September 2021

No International Reference Pricing for drugs in the US – good news for patients in the US and worldwide

No International Reference Pricing for drugs in the US

The US Government just published its “Comprehensive Plan for Addressing High Drug Prices”. It lists a number of initiatives and ideas, but does NOT mention is International Reference Pricing – and this is good news for patients in the US and worldwide (and for manufacturers, too). – Read the Akceso Advisors reflection on a latest development in the US pharmaceuticals market based on Akceso Advisors’ research related to the impact of International Reference Pricing (IRP) on patient access and innovation.

Scroll to Top
Scroll to Top